1
Arnardottir, Arna H., Haaijer-Ruskamp, Flora M., Straus, Sabine M. J., Eichler, Hans-Georg, de Graeff, Pieter A., Mol, Peter G. M.
Veröffentlicht in: Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x;
2011
Veröffentlicht in: Arnardottir , A H , Haaijer-Ruskamp , F M , Straus , S M J , Eichler , H-G , de Graeff , P A & Mol , P G M 2011 , ' Additional safety risk to exceptionally approved drugs in Europe? ' , British Journal of Clinical Pharmacology , vol. 72 , no. 3 , pp. 490-499 . https://doi.org/10.1111/j.1365-2125.2011.03995.x;
2011